Clinical Trials Logo

Clinical Trial Summary

Occurrence of inhibitors to coagulation factor VIII is diagnosed in ~30% patients with haemophilia A. Presence of inhibitor with a titre >5 BU/ml requires the use of by-passing agents: recombinant activated Factor VIIa concentrate (rFVIIa) and/or activated prothrombin complex concentrate (APCC). Similarly, haemorrhagic complications in patients with acquired haemophilia and inhibitor titre >5 BU/ml should be treated with by-passing agents.

Response to treatment with by-passing agents is patient-specific, and can vary in the same patient during subsequent bleedings. Some patients have good response to both products, however in other patients a better bleeding control is provided by one of the mentioned above agents (APCC or rFVIIa). There are clinical situations when severe bleedings requires an alternate use of both these agents.

Traditional methods of laboratory tests used post-treatment in patients with haemophilia without inhibitors are useless in the presence of inhibitor. Laboratory monitoring of therapy with by-passing agents is possible with the use of global tests for the coagulation process assessment, which are as follows: thrombin generation assay (TGA) and thromboelastometry (TEM).

Several studies revealed that TGA allows a monitoring of therapy with by-passing agents in patients with haemophilia A and inhibitor - the choice of the most effective treatment option - agent type and its dose, as well as laboratory assessment of treatment efficacy.

Up to date, laboratory tests assessing the efficacy of by-passing agents in patients with acquired haemophilia were not conducted.

In Factor VIII or IX deficiency conditions, fibrin's fibres generated by thrombin are morphologically thicker, and blood clots have increased susceptibility to fibrinolytic enzymes. Blood clot stability may be assessed with the use of thromboelastometry (TEM). We can hypothesize that simultaneous use of TGA and TEM methods may allow for an assessment of patient's individual response to therapy with by-passing agents. Clinical significance of the minimal dose of APCC and rFVIIa, needed to TGA and TEM normalization, requires further studies.

Tests' purpose: Examination of the hypothesis that simultaneous use of thrombin generation assay (TGA) and thromboelastometry (TEM) may facilitate the choice of optimal therapy with by-passing agents and laboratory monitoring of efficacy of those agents in patients with acquired haemophilia or haemophilia A with inhibitor.


Clinical Trial Description

This section is Not applicable ;


Study Design

Observational Model: Cohort, Time Perspective: Prospective


Related Conditions & MeSH terms


NCT number NCT01856751
Study type Observational
Source Stowarzyszenie Pomocy Chorym na Zakrzepice i Skazy Krwotoczne Thrombus
Contact Krystyna M Zawilska, MD, PhD
Phone 48618333949
Email k.zawilska@interia.pl
Status Recruiting
Phase N/A
Start date April 2014
Completion date June 2016

See also
  Status Clinical Trial Phase
Completed NCT02229331 - Biomechanical Determinants and Patterns Associated to the Pathophysiological Cascade of Ankle Arthropathy in Children With Haemophilia: Non-invasive In-vivo Measurement of Foot Joints in Children With Haemophilia During Gait.
Completed NCT02870114 - National Survey of People With Haemophilia in Portugal N/A
Recruiting NCT02197611 - Development of a Specific Measure for Assessing Adherence in Adult Patients With Hemophilia. N/A
Unknown status NCT02582450 - Validation of a Specific Measure for Assessment of Compliance With Treatment in Patients With Hemophilia N/A
Completed NCT05138224 - Prevalence of Autistic Spectrum Disorder (ASD) in Children With Haemophilia
Recruiting NCT03287999 - Inter Individual Variability in Initiation Pathway Activation and Regulation and Phenotypic Heterogeneity in Patients With Haemophilia A and B
Completed NCT02825667 - Effectiveness of the Myofascial Therapy in the Hemophilic Arthropathy of Ankle N/A
Completed NCT03818529 - ATHN 8: Previously Untreated Patients (PUPs) Matter Study
Completed NCT05108480 - Self-myofascial Release With Foam Roller in Patients With Hemophilic Knee Arthropathy N/A
Completed NCT02781233 - A Progressive Resistance Training Program in Patients With Haemophilia N/A
Active, not recruiting NCT02512211 - Validation of Questionnaires HAL and HEP N/A
Active, not recruiting NCT02581735 - Effectiveness of the uPatient Platform in Prophylactic Treatment in Hemophilia N/A
Not yet recruiting NCT01623960 - Quality of Life in Adult Patients With Severe Haemophilia in Turkey N/A
Recruiting NCT02191436 - Adherence to Treatment in Hemophilia N/A
Completed NCT03264014 - Combining Registry Data in Haemophilia: TARGET H N/A
Recruiting NCT02198430 - Multidisciplinary Evaluation of Patients With Hemophilia N/A
Not yet recruiting NCT06046235 - Virtual Evaluations of Joint Health Using Wearable Sensors in Persons With Haemophilia (VESPA)
Completed NCT03529474 - Psychology and Physiotherapy Approach of Chronic Pain in Patients With Hemophilia N/A
Completed NCT05425888 - Functional and Proprioceptive Status in Patients With Hemophilic Ankle Arthropathy
Recruiting NCT03914209 - Extended Half-Life (EHL) Clotting Factor for Improving the Musculoskeletal Health of Patients With Hemophilia